CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Nexavar (sorafenib) clinical coverage guideline

Defines accepted indications, contraindications, exclusions, dosing limits, and coding for sorafenib (Nexavar) for providers and utilization management staff processing medication requests for Neighborhood Health Plan of Rhode Island (via Evolent). Applies to commercial, exchange/marketplace, and Medicaid lines of business.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyNexavar (sorafenib) clinical coverage guideline

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionEnsure medication requests are supported by FDA labeling, CMS-recognized compendia, NCCN/ASCO guidelines, or acceptable peer-reviewed literature and that dosing/quantity limits are met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3Primary tumor indications addressed

400Single dose maximum (mg)

120Monthly tablet limit

Medically Necessary and Not Covered Indications

Medically Necessary / Supported Indications

ANY of

Hepatocellular carcinoma (HCC): Single‑agent sorafenib for unresectable HCC in members with Child‑Pugh Class A or B, in the subsequent line setting.
Thyroid carcinoma: Single‑agent sorafenib for locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

Not Supported / Not Covered Indications

Sorafenib is not supported for the following uses:

ANY of

Renal cell carcinoma (RCC): Not supported as initial or subsequent treatment for recurrent/metastatic RCC due to lack of Level 1 evidence showing superiority to Evolent‑recommended alternatives.
Investigational/off‑label indications lacking sufficient evidence or not supported by CMS‑recognized compendia or acceptable peer‑reviewed literature.

Absolute Contraindications / Warnings

Do not use sorafenib when any of the following apply:

ALL of

Known severe hypersensitivity to sorafenib or any component of the formulation.
Use in combination with carboplatin and paclitaxel in patients with squamous cell lung cancer.

Exclusion Criteria / Denial Conditions

Requests should be denied when any of the following exclusion criteria are met:

ANY of

Concurrent use with other tyrosine kinase inhibitors or chemotherapy.
Disease progression while receiving sorafenib.
Requested single dose exceeds 400 mg.
Requested quantity exceeds 120 tablets (200 mg) per month.
Investigational use with an off‑label indication that does not meet evidence standards (see evidence adequacy criteria).

Continuation Request Exception

Continuation requests for a not‑approvable medication may be exempt from this guideline when ALL of the following are true:

ALL of

Member has not experienced disease progression on the requested medication.
Requested medication was used within the last year without a lapse of more than 30 days of having an active authorization.
No additional medication(s) are being added to the continuation request.

Prior Authorization, Documentation, and Denial Risks

Prior Authorization

Prior authorization processing

Evolent is responsible for processing all medication requests from network ordering providers; medications not authorized by Evolent may be deemed not approvable and therefore not reimbursable.

All sorafenib (Nexavar) medication requests must be submitted to Evolent for prior authorization processing.

Documentation Required

Support use with authoritative sources

Ensure the request is supported by one of the following: FDA-approved product labeling, CMS-recognized compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

Include citations to the specific FDA labeling, CMS compendium entry, NCCN/ASCO guideline, or the peer‑reviewed article used to justify the request.

Denial Risk

Dosing and quantity limits

Requests that exceed the policy limits for single-dose or monthly quantity are subject to denial per the exclusion criteria.

Single-dose limit: requests exceeding 400 mg may be denied.
Monthly limit: requests exceeding 120 tablets (200 mg strength) per month may be denied.

Documentation Required

Evidence adequacy for off-label use

For off-label or investigational indications, provide evidence that adequately represents the patient and cancer characteristics, details of the administered regimen, clinically meaningful outcomes per ASCO standards, and appropriate study design quality.

Demonstrate that published evidence includes patients and cancer types comparable to the member.
Describe the exact regimen(s) used in the evidence (drugs, doses, schedules) and how they match the requested therapy.
Show clinically meaningful outcomes (ASCO-recommended thresholds, e.g., hazard ratio <0.80 and OS/PFS benefit typically ≥3 months) where applicable.
Address study design quality (randomization, controls, sample size) or justify why non-randomized data are acceptable.

Clinical and Evidence Context

Sorafenib (Nexavar) is an oral multikinase inhibitor used in oncology and included in this guideline with both FDA‑approved and recognized off‑label indications. The agent’s regulatory and evidence base is documented in the product labeling and peer‑reviewed trials, and Evolent requires requests be supported by FDA labeling, CMS‑recognized compendia, NCCN/ASCO guidelines, or acceptable peer‑reviewed literature.

Clinical trial evidence supports single‑agent sorafenib for unresectable hepatocellular carcinoma (HCC): the SHARP trial demonstrated benefit in advanced HCC and this guideline supports sorafenib as a single agent in members with Child‑Pugh Class A or B unresectable HCC in the subsequent‑line setting.

Sorafenib is also supported for locally recurrent or metastatic, progressive differentiated thyroid carcinoma refractory to radioactive iodine, based on randomized phase 3 data (DECISION trial).

For renal cell carcinoma (RCC), the policy does not support sorafenib as initial or subsequent treatment for recurrent/metastatic disease because there is a lack of Level‑1 evidence showing superiority to Evolent‑recommended alternative agents/regimens.

Key references for these conclusions include the SHARP trial for HCC and the DECISION trial for radioactive‑iodine refractory differentiated thyroid carcinoma, as well as the Nexavar prescribing information and compendia cited in the guideline.

Policy Dates

November 2025RevisionLatest

Converted to the new Evolent guideline template; replaced prior version UM ONC_1194; updated indication section; added Child‑Pugh Score table under the HCC indication; updated references.

November 2024Revision

Updated NCH verbiage to Evolent.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyNexavar (sorafenib) clinical coverage guideline

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionEnsure medication requests are supported by FDA labeling, CMS-recognized compendia, NCCN/ASCO guidelines, or acceptable peer-reviewed literature and that dosing/quantity limits are met.

SourceLink

On This Page

OpenPayer

Nexavar (sorafenib) clinical coverage guideline

Medically Necessary and Not Covered Indications

Numeric and Clinical Thresholds

Billing Codes

Prior Authorization, Documentation, and Denial Risks

Clinical and Evidence Context

Key Definitions

Policy Dates

Nexavar (sorafenib) clinical coverage guideline

Medically Necessary and Not Covered Indications

Numeric and Clinical Thresholds

Billing Codes

Prior Authorization, Documentation, and Denial Risks

Clinical and Evidence Context

Key Definitions

Cross-References

Policy Dates